A phase 3 open-label extension study has shown that serious adverse events were rare and the skin continued to be largely clear in adolescents having moderate-to-severe atopic dermatitis (AD), who were administered dupilumab, for up to 52 weeks.

Around 86% of 50 remaining patients weighing under 60 kg had achieved 75% improvement (EASI-75; Eczema Area and Severity Index) at 1 year, while 77% of 51 remaining patients weighing more than 60 kg attained this level of improvement. Only 1.7% of 294 patients reported serious treatment-emergent adverse events (TEAEs). Additionally, 37% of 52 patients weighing below 60 kg attained an Investigator Global Assessment (IGA) of 0/1 at 52 weeks. Among 51 patients weighing more than 60 kg, 49% attained an IGA of 0/1. The findings were presented at the meeting of the World Congress of Pediatric Dermatology in a poster… (Medscape)